Shares of Johnson & Johnson (NYSE:JNJ) have received a consensus recommendation of “Hold” from the twenty-one ratings firms that are presently covering the company, MarketBeat.com reports. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have issued a buy rating on the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $133.02.

Several research analysts have recently weighed in on the stock. J P Morgan Chase & Co lifted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 16th. Wells Fargo & Company reissued a “market perform” rating and issued a $135.00 target price (up from $132.00) on shares of Johnson & Johnson in a research report on Thursday, July 6th. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. UBS AG reissued a “buy” rating and issued a $148.00 target price (up from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. Finally, BTIG Research downgraded shares of Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 target price on the stock. in a research report on Friday, July 21st.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total value of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.

A number of hedge funds and other institutional investors have recently bought and sold shares of JNJ. Lau Associates LLC lifted its stake in Johnson & Johnson by 12.8% in the first quarter. Lau Associates LLC now owns 46,878 shares of the company’s stock valued at $5,839,000 after acquiring an additional 5,335 shares during the last quarter. Bath Savings Trust Co lifted its stake in Johnson & Johnson by 2.5% in the first quarter. Bath Savings Trust Co now owns 22,083 shares of the company’s stock valued at $2,750,000 after acquiring an additional 542 shares during the last quarter. Liberty Capital Management Inc. lifted its stake in Johnson & Johnson by 0.7% in the first quarter. Liberty Capital Management Inc. now owns 7,226 shares of the company’s stock valued at $900,000 after acquiring an additional 50 shares during the last quarter. McQueen Ball & Associates Inc. lifted its stake in Johnson & Johnson by 0.3% in the first quarter. McQueen Ball & Associates Inc. now owns 27,073 shares of the company’s stock valued at $3,372,000 after acquiring an additional 74 shares during the last quarter. Finally, Capital Investment Services of America Inc. lifted its stake in Johnson & Johnson by 3.3% in the first quarter. Capital Investment Services of America Inc. now owns 12,404 shares of the company’s stock valued at $1,545,000 after acquiring an additional 400 shares during the last quarter. Hedge funds and other institutional investors own 66.00% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/17/johnson-johnson-jnj-given-consensus-recommendation-of-hold-by-analysts.html.

Johnson & Johnson (NYSE:JNJ) opened at 134.45 on Friday. The stock has a market cap of $360.86 billion, a P/E ratio of 22.75 and a beta of 0.79. Johnson & Johnson has a 52 week low of $109.32 and a 52 week high of $137.08. The company’s 50 day moving average is $132.62 and its 200 day moving average is $129.18.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analysts’ expectations of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The business’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.74 EPS. Equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.50%. The ex-dividend date was Friday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 56.76%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.